Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

Managing Symptom Clusters in Patients on Hemodialysis With CKD-aP

3 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test Skip straight to the post-test if you have already participated in this activity.
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    Patients undergoing dialysis frequently experience symptom clusters resulting from chronic kidney disease-associated pruritus, or CKD-aP. These clusters include severe itching, compromised sleep quality, heightened levels of depression, and diminished quality of life. CKD-aP is associated with adverse clinical outcomes, such as susceptibility to infections, high rates of hospitalization, and elevated mortality. Join the experts as they take a deep dive into the multidisciplinary approach needed for the assessment, treatment, and monitoring of CKD-aP-associated symptom clusters.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Kelly Chenlei Li, MBBS, FRACP
    Nephrologist and Palliative Medicine Physician
    St. George Hospital
    Sydney, NSW, Australia

    Dr. Li has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: CSL Vifor 

    Faculty:
    Paul Bennett, RN, MHSM, PhD, FISN
    School of Nursing and Midwifery
    Griffith University
    Queensland, Australia

    Dr. Bennett has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Royalty: CSL Vifor

    Thilo Krüger, MD, PhD
    Deputy Chief Medical Officer Germany
    Internist and Nephrologist
    DaVita Clinical Research Germany GmbH
    Duesseldorf, Germany

    Dr. Krüger has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: CSL Vifor
    Contracted Research: CSL Vifor 

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Kathleen Sheridan, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify common symptom clusters associated with chronic kidney disease-associated pruritus (CKD-aP)
    • Assess the severity and progression of symptom clusters in patients with CKD-aP
    • Develop a multidisciplinary treatment plan to manage symptom clusters in patients undergoing dialysis
  • Target Audience

    This activity has been designed to meet the educational needs of nephrologists and dermatologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with chronic kidney disease-associated pruritus.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until July 11, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 contact hour/0.05 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-25-001-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
Comments
  • Overview

    Patients undergoing dialysis frequently experience symptom clusters resulting from chronic kidney disease-associated pruritus, or CKD-aP. These clusters include severe itching, compromised sleep quality, heightened levels of depression, and diminished quality of life. CKD-aP is associated with adverse clinical outcomes, such as susceptibility to infections, high rates of hospitalization, and elevated mortality. Join the experts as they take a deep dive into the multidisciplinary approach needed for the assessment, treatment, and monitoring of CKD-aP-associated symptom clusters.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Kelly Chenlei Li, MBBS, FRACP
    Nephrologist and Palliative Medicine Physician
    St. George Hospital
    Sydney, NSW, Australia

    Dr. Li has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: CSL Vifor 

    Faculty:
    Paul Bennett, RN, MHSM, PhD, FISN
    School of Nursing and Midwifery
    Griffith University
    Queensland, Australia

    Dr. Bennett has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Royalty: CSL Vifor

    Thilo Krüger, MD, PhD
    Deputy Chief Medical Officer Germany
    Internist and Nephrologist
    DaVita Clinical Research Germany GmbH
    Duesseldorf, Germany

    Dr. Krüger has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: CSL Vifor
    Contracted Research: CSL Vifor 

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Kathleen Sheridan, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify common symptom clusters associated with chronic kidney disease-associated pruritus (CKD-aP)
    • Assess the severity and progression of symptom clusters in patients with CKD-aP
    • Develop a multidisciplinary treatment plan to manage symptom clusters in patients undergoing dialysis
  • Target Audience

    This activity has been designed to meet the educational needs of nephrologists and dermatologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with chronic kidney disease-associated pruritus.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until July 11, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 contact hour/0.05 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-25-001-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule9 Oct 2024